Effect of Leaking Foveal Microaneurysms on the Treatment of Center-Involving Diabetic Macular Edema: A Pilot Study.
Aged
Analysis of Variance
Angiogenesis Inhibitors
/ therapeutic use
Combined Modality Therapy
Diabetic Retinopathy
/ physiopathology
Female
Fovea Centralis
/ pathology
Humans
Intravitreal Injections
Laser Coagulation
/ methods
Macula Lutea
/ pathology
Macular Edema
/ physiopathology
Male
Microaneurysm
/ physiopathology
Middle Aged
Pilot Projects
Prospective Studies
Ranibizumab
/ therapeutic use
Visual Acuity
/ physiology
Capillary nonperfusion
Diabetic macular edema
Focal/grid laser
Short-pulse laser
Vascular endothelial growth factor
Journal
Ophthalmic research
ISSN: 1423-0259
Titre abrégé: Ophthalmic Res
Pays: Switzerland
ID NLM: 0267442
Informations de publication
Date de publication:
2019
2019
Historique:
received:
02
05
2018
accepted:
09
07
2018
pubmed:
12
10
2018
medline:
12
2
2019
entrez:
11
10
2018
Statut:
ppublish
Résumé
Evaluate the effect of foveal leaking microaneurysms (MAs) on the required number of intravitreal ranibiz-umab (IVR) injections in the treatment of center-involving diabetic macular edema (DME) when treated with focal/grid laser. A pilot study of prospective, nonrandomized, multicenter clinical trial. This study enrolled 21 eyes with DME for which pro re nata IVR injections were combined with short-pulse focal/grid laser. At 12 months, best-corrected visual acuity (BCVA), central subfield macular thickness (CMT), and the required number of IVRs to maintain CMT < 300 µm were compared between eyes with or without foveal leaking MAs, termed the MA(+) and MA(-) groups, respectively. Significant CMT improvements (p < 0.0001) and increased BCVA of 4.0 ± 8.5 letters were observed at 12 months. The MA(-) group required significantly fewer IVRs than did the MA(+) group (mean: 4.9 ± 3.0 vs. 8.6 ± 3.0; p = 0.0306). In the latter 6 months of the 1-year follow-up, 50% (4/8) of MA(-) eyes did not require any IVR administration to sustain CMT < 300 µm. A combination therapy of short-pulse focal/grid laser and reduced IVR injections appeared noninferior to previous reports of IVR monotherapy. Further large-scale investigations are warranted.
Identifiants
pubmed: 30304729
pii: 000492005
doi: 10.1159/000492005
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Ranibizumab
ZL1R02VT79
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
10-18Informations de copyright
© 2018 S. Karger AG, Basel.